Tenax Therapeutics Inc. (TENX)
6.29
-0.09 (-1.41%)
At close: Jan 28, 2025, 1:58 PM
undefined% (undefined)
| Bid | 6.15 |
| Market Cap | 21.44M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -13.05 |
| PE Ratio (ttm) | -0.48 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.28 |
| Volume | 8,616 |
| Avg. Volume (20D) | 51,681 |
| Open | 6.30 |
| Previous Close | 6.38 |
| Day's Range | 6.17 - 6.46 |
| 52-Week Range | 2.77 - 21.46 |
| Beta | undefined |
About TENX
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertensi...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 4, 1994
Employees 5
Stock Exchange NASDAQ
Ticker Symbol TENX
Website https://www.tenaxthera.com
Analyst Forecast
According to 4 analyst ratings, the average rating for TENX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 154.37% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
+10.65%
Tenax Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
3 months ago
+12.46%
Tenax Therapeutics shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a $16 price target.
